Transcode therapeutics stock.

Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00.BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has closed a registered direct offering, selling 5,000,000 shares of common stock at $0.242 per share, resulting in gross proceeds of $1.2 million. The company plans to use the net proceeds for clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.If you are looking for stocks with good return, Transcode Therapeutics Inc stock can be a bad, high-risk 1-year investment option. Transcode Therapeutics Inc real time quote is equal to 0.240 USD at 2023-11-26, but your current investment may be devalued in …TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously …

Why TransCode Therapeutics Stock Is Trading Higher Premarket Today. TransCode Therapeutics Inc (NASDAQ: RNAZ) announced acceptance for publication by Frontiers in Molecular Biosciences of a ... TransCode Therapeutics hasn’t yet revealed details of the proposed public stock offering. RNAZ Trading at -49.61% from the 50-Day Moving Average After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.06% of loss for the given period.

Get a real-time TransCode Therapeutics, Inc. (RNAZ) stock price quote with breaking news, financials, statistics, charts and more.

TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same. However, despite significant efforts made in the past several ... TransCode Therapeutics Stock Forecast. All Analysts Top Analysts RNAZ's stock price has decreased by -97.55% in the past year and price targets may not have had time to catch up. Stock Price Forecast. According to 1 stock analyst, the 12-month stock price forecast for RNAZ stock stock is $3.00, which predicts an increase of …TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.TSLA Tesla, Inc. Common Stock $230.05 +0.01 BETR Better Home & Finance Holding Company Class A Common Stock $1.56 +0.41 +35.65% Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the...

The TransCode Therapeutics, Inc. stock price gained 6.25% on the last trading day (Wednesday, 22nd Nov 2023), rising from $0.230 to $0.245. During the last trading day the stock fluctuated 13.64% from a day low at $0.220 to a day high of $0.250. The price has fallen in 7 of the last 10 days and is down by -36.25% for this period.

Dec 4, 2023 · BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ...

The 1-for-20 reverse stock split will automatically convert 20 current shares of TransCode’s common stock into one new share of common stock. No fractional shares will be issued in connection ...Dec 4, 2023 · BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA ... Nov 30, 2023 · BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock ... BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...Sep 25, 2023 · AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ... Get the latest Galera Therapeutics Inc (GRTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.On May 22, 2023, TransCode Therapeutics made an announcement that shook the stock market. The company revealed that it would be implementing a 1-for-20 reverse stock split. This move means that every 20 shares of TransCode’s current common stock will be combined into one new share of common stock.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ:RNAZ) saw its shares drive up 300% earlier this ...BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the Company), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics ...Transcode therapeutics, inc. Has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock. The company is an rna oncology company committed to more effectively treating cancer using rna therapeutics. The gross proceeds from the offering are expected to be approximately $1.2 million.Among that is what’s happening with shares of PTC Therapeutics (NASDAQ:PTCT) stock, TransCode Therapeutics (NASDAQ:RNAZ) stock and Apollomics (NASDAQ:APLM) stock today. All of that info is ...TransCode Therapeutics Inc RNAZ shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 clinical trial.BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full …BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief …Dec 7, 2022 · TransCode Therapeutics (NASDAQ: RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won’t pursue a plan to sell 12 ... BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating ...4 hours ago · The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ... TransCode Therapeutics, Inc. BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA ...BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...Find the latest TransCode Therapeutics Inc (RNAZ) discussion and analysis from iHub's community of investors.On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 ...TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher after the company announced results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human ...

2,091.70 +34.50(+1.68%) TransCode Therapeutics, Inc. (RNAZ) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 0.2190 -0.0270 (-10.98%) At close: 04:00PM EST 0.2210 +0.00...

Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...

Jun 6, 2023 · Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per ... TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules. BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode...Sep 25, 2023 · AboutTransCodeTherapeutics. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The Company has created a platform of ... WATERTOWN, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $175 million of …BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient ...4 hours ago · The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ... BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...UNITED STATES . SECURITIES AND EXCHANGE COMMISSION . Washington, D.C. 20549 FORM 8-K. CURRENT REPORT . Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934About TransCode Therapeutics TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of …Oct 26, 2023 · BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

Transcode therapeutics, inc. Has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock. The company is an rna oncology company committed to more effectively treating cancer using rna therapeutics. The gross proceeds from the offering are expected to be approximately $1.2 million.Sep 26, 2023 · According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ... BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. RNAZ (the “Company”), an RNA oncology company committed to more effectively treating …Instagram:https://instagram. quantum ai stock priceendo opioid settlementwhat are candlestick chartsgo pro stock About TransCode Therapeutics TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of … winmark1971 liberty half dollar value TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously … good etfs for roth ira TransCode Therapeutics (NASDAQ:RNAZ) Thursday announced the commencement of an underwritten public offering of shares of its common stock.In addition, the company said it expects to grant the ...VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: …Discover historical prices for RNAZ stock on Yahoo Finance. View daily, weekly or monthly format back to when TransCode Therapeutics, Inc. stock was issued.